DaShenLin Pharmaceutical Group Co., Ltd. (SHA: 603233)

Market Cap	18.31B
Revenue (ttm)	26.54B
Net Income (ttm)	850.26M
Shares Out	1.14B
EPS (ttm)	0.75
PE Ratio	21.47
Forward PE	18.64
Dividend	0.62 (3.81%)
Ex-Dividend Date	Oct 23, 2024

Volume	8,068,441
Open	16.14
Previous Close	16.12
Day's Range	15.98 - 16.41
52-Week Range	11.92 - 27.10
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About DaShenLin Pharmaceutical Group

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. It provides Chinese and western patent medicines, ginseng tonic medicinal materials and Chinese herbal pieces, health care products, medical equipment, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 45,466
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603233

Financial Performance

In 2023, DaShenLin Pharmaceutical Group's revenue was 24.53 billion, an increase of 15.45% compared to the previous year's 21.25 billion. Earnings were 1.17 billion, an increase of 12.63%.